Yousif Capital Management LLC Has $1.63 Million Stake in Roivant Sciences Ltd. $ROIV

Yousif Capital Management LLC lowered its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 2.8% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 144,789 shares of the company’s stock after selling 4,102 shares during the quarter. Yousif Capital Management LLC’s holdings in Roivant Sciences were worth $1,632,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of ROIV. Amundi increased its stake in Roivant Sciences by 18.1% in the first quarter. Amundi now owns 398,729 shares of the company’s stock valued at $3,991,000 after purchasing an additional 61,214 shares in the last quarter. Bank of New York Mellon Corp increased its position in Roivant Sciences by 16.3% in the 1st quarter. Bank of New York Mellon Corp now owns 4,000,181 shares of the company’s stock valued at $40,362,000 after buying an additional 560,641 shares in the last quarter. Inspire Investing LLC acquired a new position in Roivant Sciences during the 1st quarter worth approximately $303,000. GAMMA Investing LLC boosted its holdings in Roivant Sciences by 83.0% in the first quarter. GAMMA Investing LLC now owns 6,493 shares of the company’s stock worth $66,000 after acquiring an additional 2,945 shares in the last quarter. Finally, Peak Financial Advisors LLC bought a new position in Roivant Sciences in the second quarter worth approximately $472,000. 64.76% of the stock is owned by institutional investors.

Insider Activity at Roivant Sciences

In other news, major shareholder Vivek Ramaswamy sold 1,195,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 3rd. The stock was sold at an average price of $12.50, for a total value of $14,937,500.00. Following the transaction, the insider owned 36,089,108 shares in the company, valued at $451,113,850. The trade was a 3.21% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Eric Venker sold 683,818 shares of Roivant Sciences stock in a transaction on Friday, September 19th. The stock was sold at an average price of $14.95, for a total value of $10,223,079.10. Following the sale, the chief executive officer owned 1,969,767 shares in the company, valued at $29,448,016.65. This trade represents a 25.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 5,228,958 shares of company stock worth $76,447,638. Insiders own 10.80% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. Jefferies Financial Group upped their target price on Roivant Sciences from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Thursday, September 18th. Bank of America upped their price objective on shares of Roivant Sciences from $12.00 to $16.50 and gave the stock a “neutral” rating in a report on Thursday, September 18th. Leerink Partners raised their price objective on shares of Roivant Sciences from $18.00 to $22.00 and gave the company an “outperform” rating in a research note on Thursday, September 18th. JPMorgan Chase & Co. boosted their target price on shares of Roivant Sciences from $16.00 to $20.00 and gave the stock an “overweight” rating in a research report on Thursday, September 18th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Roivant Sciences in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Roivant Sciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $19.94.

Roivant Sciences Price Performance

Shares of ROIV stock opened at $17.26 on Monday. The firm has a 50-day moving average of $13.97 and a 200-day moving average of $12.03. Roivant Sciences Ltd. has a one year low of $8.73 and a one year high of $17.33. The company has a market cap of $11.79 billion, a P/E ratio of -24.66 and a beta of 1.20.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.